source
- Weighing the risks of CAR T in autoimmune disease as Kyverna nears marketNot a month after reports of three deaths in autoimmune trials for Novartis' CAR T cell therapy ignited a debate about the use of these treatments in nonfatal diseases, Kyverna Therapeutics reporte…BioSpace · 16d ago↗ source
- Novartis signs $7.8 billion deal with Abogen for mRNA-encoded autoimmune T-cell engagerNovartis announced it will pay $575 million upfront to Abogen Biosciences for an mRNA-encoded T-cell engager that has shown early clinical activity in autoimmune disease. The agreement includes up…